JP2023541375A - α１Ａ－アドレナリン受容体アゴニスト及び使用方法 - Google Patents

α１Ａ－アドレナリン受容体アゴニスト及び使用方法 Download PDF

Info

Publication number
JP2023541375A
JP2023541375A JP2023513294A JP2023513294A JP2023541375A JP 2023541375 A JP2023541375 A JP 2023541375A JP 2023513294 A JP2023513294 A JP 2023513294A JP 2023513294 A JP2023513294 A JP 2023513294A JP 2023541375 A JP2023541375 A JP 2023541375A
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
formula
compound
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541375A5 (cg-RX-API-DMAC7.html
Inventor
デビッド スコット カーター
クンデ オーヤン
アンソニー ピー． フォード
ウェイ チェン
Original Assignee
キュラセン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュラセン セラピューティクス インコーポレイテッド filed Critical キュラセン セラピューティクス インコーポレイテッド
Publication of JP2023541375A publication Critical patent/JP2023541375A/ja
Publication of JP2023541375A5 publication Critical patent/JP2023541375A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023513294A 2020-08-27 2021-08-26 α１Ａ－アドレナリン受容体アゴニスト及び使用方法 Pending JP2023541375A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063071297P 2020-08-27 2020-08-27
US63/071,297 2020-08-27
PCT/US2021/047779 WO2022047052A1 (en) 2020-08-27 2021-08-26 α1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE

Publications (2)

Publication Number Publication Date
JP2023541375A true JP2023541375A (ja) 2023-10-02
JP2023541375A5 JP2023541375A5 (cg-RX-API-DMAC7.html) 2024-09-02

Family

ID=80355724

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513294A Pending JP2023541375A (ja) 2020-08-27 2021-08-26 α１Ａ－アドレナリン受容体アゴニスト及び使用方法

Country Status (9)

Country Link
US (1) US20230312524A1 (cg-RX-API-DMAC7.html)
EP (1) EP4204404A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023541375A (cg-RX-API-DMAC7.html)
KR (1) KR20230058066A (cg-RX-API-DMAC7.html)
CN (1) CN115884964A (cg-RX-API-DMAC7.html)
AU (1) AU2021334327A1 (cg-RX-API-DMAC7.html)
CA (1) CA3187076A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023002276A (cg-RX-API-DMAC7.html)
WO (1) WO2022047052A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622949B1 (en) 2022-08-04 2023-04-11 Gad M. Gilad Agmatine compositions for treatment of osteoarthritis

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1302902B (cg-RX-API-DMAC7.html) *
US2161938A (en) * 1934-07-31 1939-06-13 Soc Of Chemical Ind Imidazolines
US2919274A (en) * 1957-09-17 1959-12-29 Sahyun Melville Amidines
US3423423A (en) * 1967-04-04 1969-01-21 Dow Chemical Co 2-(2,4,5-trichlorobenzyl)-2-imidazoline
JPS51106739A (en) * 1975-03-12 1976-09-21 Takeda Chemical Industries Ltd Satsuchu satsudanizai
JPS62145067A (ja) * 1985-12-11 1987-06-29 アボツト　ラボラトリ−ズ ２−〔（３，５−ジハロ−４−アミノベンジル）〕イミダゾリン類
JPH1171353A (ja) * 1997-06-23 1999-03-16 F Hoffmann La Roche Ag フェニル−及びアミノフェニル−アルキルスルホンアミド及び尿素誘導体
CA2246027A1 (en) * 1998-08-27 2000-02-27 Virginia Commonwealth University Benzylamidine derivatives with serotonin receptor binding activity
JP2000511903A (ja) * 1996-06-07 2000-09-12 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のための選択性β▲下３▼作動薬としてのオキサジアゾール・ベンゼンスルホンアミド
JP2005534628A (ja) * 2002-04-23 2005-11-17 エフ．ホフマン−ラ　ロシュ　アーゲー イミダゾリニルメチルアラルキルスルホンアミド類
JP2009524617A (ja) * 2006-01-27 2009-07-02 エフ．ホフマン−ラ ロシュ アーゲー 置換２−イミダゾール又はイミダゾリン誘導体の使用
JP2009256240A (ja) * 2008-04-16 2009-11-05 Univ Of Fukui イミダゾリン誘導体
JP2011511026A (ja) * 2008-02-04 2011-04-07 エフ．ホフマン−ラ ロシュ アーゲー 新規イミダゾリニルメチルアリールスルホンアミド
JP2011511023A (ja) * 2008-02-04 2011-04-07 エフ．ホフマン−ラ ロシュ アーゲー 新規イミダゾリニルメチルアリールスルホンアミド
JP2011511024A (ja) * 2008-02-04 2011-04-07 エフ．ホフマン−ラ ロシュ アーゲー 尿失禁の処置用のα−１Ａアドレナリン作動性部分アゴニストとしてのＮ−［３−ブロモ−２−クロロ−４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イルメチル）−フェニル］−メタンスルホンアミド
JP2013199432A (ja) * 2011-02-21 2013-10-03 Univ Of Fukui イミダゾリン誘導体
WO2016105448A1 (en) * 2014-12-22 2016-06-30 Darryl Rideout Imidazoline receptor type 1 ligands for use as therapeutics
US20180230105A1 (en) * 2017-01-13 2018-08-16 Regents Of The University Of Minnesota Therapeutic compounds
JP2019506459A (ja) * 2016-02-26 2019-03-07 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア アルファ−１−アドレナリン受容体アゴニスト療法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100120A2 (en) * 2008-02-04 2009-08-13 Neurogen Corporation Pyridinyl-substituted piperazinyl oxoethyl tetrahydropyrazolopyridines
WO2021081292A1 (en) * 2019-10-25 2021-04-29 Curasen Therapeutics, Inc. METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH α1A-AR PARTIAL AGONISTS

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1302902B (cg-RX-API-DMAC7.html) *
US2161938A (en) * 1934-07-31 1939-06-13 Soc Of Chemical Ind Imidazolines
US2919274A (en) * 1957-09-17 1959-12-29 Sahyun Melville Amidines
US3423423A (en) * 1967-04-04 1969-01-21 Dow Chemical Co 2-(2,4,5-trichlorobenzyl)-2-imidazoline
JPS51106739A (en) * 1975-03-12 1976-09-21 Takeda Chemical Industries Ltd Satsuchu satsudanizai
JPS62145067A (ja) * 1985-12-11 1987-06-29 アボツト　ラボラトリ−ズ ２−〔（３，５−ジハロ−４−アミノベンジル）〕イミダゾリン類
JP2000511903A (ja) * 1996-06-07 2000-09-12 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のための選択性β▲下３▼作動薬としてのオキサジアゾール・ベンゼンスルホンアミド
JPH1171353A (ja) * 1997-06-23 1999-03-16 F Hoffmann La Roche Ag フェニル−及びアミノフェニル−アルキルスルホンアミド及び尿素誘導体
CA2246027A1 (en) * 1998-08-27 2000-02-27 Virginia Commonwealth University Benzylamidine derivatives with serotonin receptor binding activity
JP2005534628A (ja) * 2002-04-23 2005-11-17 エフ．ホフマン−ラ　ロシュ　アーゲー イミダゾリニルメチルアラルキルスルホンアミド類
JP2009524617A (ja) * 2006-01-27 2009-07-02 エフ．ホフマン−ラ ロシュ アーゲー 置換２−イミダゾール又はイミダゾリン誘導体の使用
JP2011511026A (ja) * 2008-02-04 2011-04-07 エフ．ホフマン−ラ ロシュ アーゲー 新規イミダゾリニルメチルアリールスルホンアミド
JP2011511023A (ja) * 2008-02-04 2011-04-07 エフ．ホフマン−ラ ロシュ アーゲー 新規イミダゾリニルメチルアリールスルホンアミド
JP2011511024A (ja) * 2008-02-04 2011-04-07 エフ．ホフマン−ラ ロシュ アーゲー 尿失禁の処置用のα−１Ａアドレナリン作動性部分アゴニストとしてのＮ−［３−ブロモ−２−クロロ−４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イルメチル）−フェニル］−メタンスルホンアミド
JP2009256240A (ja) * 2008-04-16 2009-11-05 Univ Of Fukui イミダゾリン誘導体
JP2013199432A (ja) * 2011-02-21 2013-10-03 Univ Of Fukui イミダゾリン誘導体
WO2016105448A1 (en) * 2014-12-22 2016-06-30 Darryl Rideout Imidazoline receptor type 1 ligands for use as therapeutics
JP2019506459A (ja) * 2016-02-26 2019-03-07 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア アルファ−１−アドレナリン受容体アゴニスト療法
US20180230105A1 (en) * 2017-01-13 2018-08-16 Regents Of The University Of Minnesota Therapeutic compounds

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"RN 1368426-44-1 等（全２９種）", DATABASE REGISTRY [ONLINE], JPN7025003051, 15 April 2012 (2012-04-15), ISSN: 0005747788 *
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. Vol.14(18), JPN6025027989, 2004, pages 4697 - 4699, ISSN: 0005637117 *
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. Vol.22(16), JPN6025027987, 2012, pages 5244 - 5248, ISSN: 0005637115 *
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. Vol.25(16), JPN6025027986, 2015, pages 3368 - 3372, ISSN: 0005637114 *
JOURNAL OF MEDICINAL CHEMISTRY, vol. Vol.33(4), JPN6025027984, 1990, pages 1138 - 1144, ISSN: 0005747786 *
JOURNAL OF MEDICINAL CHEMISTRY, vol. Vol.41(13), JPN6025027985, 1998, pages 2243 - 2251, ISSN: 0005747787 *
NATURE CHEMICAL BIOLOGY, vol. Vol.7(12), JPN6025027988, 2011, pages 909 - 915, ISSN: 0005637116 *
NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. Vol.344(4), JPN6025027983, 1991, pages 454 - 463, ISSN: 0005747785 *

Also Published As

Publication number Publication date
AU2021334327A1 (en) 2023-05-04
EP4204404A1 (en) 2023-07-05
EP4204404A4 (en) 2024-12-25
CA3187076A1 (en) 2022-03-03
WO2022047052A1 (en) 2022-03-03
CN115884964A (zh) 2023-03-31
MX2023002276A (es) 2023-03-10
KR20230058066A (ko) 2023-05-02
US20230312524A1 (en) 2023-10-05
AU2021334327A9 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
TWI877182B (zh) β腎上腺素激動劑及其使用方法
TWI886121B (zh) β腎上腺素激動劑及其使用方法
US7838544B2 (en) Heterocyclic inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and methods of using the same
US20070293529A1 (en) Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
US20070213311A1 (en) Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
ES2958391T3 (es) Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
US8563742B2 (en) Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
WO2015008229A1 (en) Autotaxin inhibitors
WO2020163236A1 (en) Treating long qt syndrome
JP2023541375A (ja) α１Ａ－アドレナリン受容体アゴニスト及び使用方法
US20180127464A1 (en) Novel epha4 inhibitors targeting its ligand binding domain
JP2023552292A (ja) βアドレナリンアゴニスト及びその使用方法
JP2025512777A (ja) アルファ１ａ－アドレナリン受容体アゴニスト及びその使用方法
JP6401254B2 (ja) プロキネシチン受容体のモジュレータとしての１−スルホニルピペリジン誘導体
US20220315534A1 (en) Beta adrenergic agonist and methods of using the same
CN117999072A (zh) β肾上腺素能激动剂和其使用方法
BR112017009276B1 (pt) Pirazolo[1,5-a]pirimidinas substituídas, composição farmacêutica e seus usos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230224

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251008

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260407